carmustine has been researched along with Epilepsy in 7 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Anticonvulsant therapy is usually recommended before surgery in all patients affected by high grade glioma who are planned to be treated with Carmustine 1,3-bis [2 chloroetyl]-1-nitrosurea, or BCNU) wafers." | 5.15 | Postoperative seizure in high grade glioma patients treated with BCNU wafers. A mono-institutional experience. ( Ciccarino, P; d'Avella, D; Del Moro, G; Della Puppa, A; Denaro, L; Lombardi, G; Manara, R; Rossetto, M; Rotilio, A; Scienza, R, 2011) |
| "Factors predicting adverse events following implantation with wafers containing 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine, BCNU), which is used in local chemotherapy for malignant gliomas (MGs), are unknown." | 4.12 | Cerebral Edema Due to Chemotherapeutic Wafer Implantation for Malignant Glioma: Registry Study of Correlation with Perioperative Epileptic Seizures. ( Fujii, Y; Goto, T; Hanaoka, Y; Hardian, RF; Hongo, K; Horiuchi, T; Kato, H; Ogiwara, T, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, Y | 1 |
| Ogiwara, T | 1 |
| Kato, H | 1 |
| Hanaoka, Y | 1 |
| Hardian, RF | 1 |
| Goto, T | 1 |
| Hongo, K | 1 |
| Horiuchi, T | 1 |
| Pennacchio, P | 1 |
| Noé, F | 1 |
| Gnatkovsky, V | 1 |
| Moroni, RF | 3 |
| Zucca, I | 1 |
| Regondi, MC | 3 |
| Inverardi, F | 3 |
| de Curtis, M | 1 |
| Frassoni, C | 3 |
| Cipelletti, B | 1 |
| Spreafico, R | 2 |
| Della Puppa, A | 1 |
| Denaro, L | 1 |
| Rossetto, M | 1 |
| Ciccarino, P | 1 |
| Manara, R | 1 |
| Lombardi, G | 1 |
| Del Moro, G | 1 |
| Rotilio, A | 1 |
| d'Avella, D | 1 |
| Scienza, R | 1 |
| Benardete, EA | 1 |
| Kriegstein, AR | 1 |
| Panzica, F | 1 |
| Yamamoto, YL | 1 |
| Thompson, CJ | 1 |
| Diksic, M | 1 |
| Meyer, E | 1 |
| Feindel, WH | 1 |
1 review available for carmustine and Epilepsy
| Article | Year |
|---|---|
Positron emission tomography.
Topics: Adolescent; Adult; Aged; Aging; Brain; Brain Diseases; Brain Neoplasms; Carmustine; Cerebrovascular | 1984 |
1 trial available for carmustine and Epilepsy
| Article | Year |
|---|---|
Postoperative seizure in high grade glioma patients treated with BCNU wafers. A mono-institutional experience.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials, Ph | 2011 |
5 other studies available for carmustine and Epilepsy
| Article | Year |
|---|---|
Cerebral Edema Due to Chemotherapeutic Wafer Implantation for Malignant Glioma: Registry Study of Correlation with Perioperative Epileptic Seizures.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine; Combined Modalit | 2022 |
Increased pCREB expression and the spontaneous epileptiform activity in a BCNU-treated rat model of cortical dysplasia.
Topics: Age Factors; Animals; Antineoplastic Agents, Alkylating; Brain; Calbindins; Carmustine; CREB-Binding | 2015 |
Development of cortical malformations in BCNU-treated rat, model of cortical dysplasia.
Topics: Animals; Animals, Newborn; Carmustine; Cell Differentiation; Cell Movement; Disease Models, Animal; | 2011 |
Increased excitability and decreased sensitivity to GABA in an animal model of dysplastic cortex.
Topics: Animals; Bicuculline; Carmustine; Cerebral Cortex; Disease Models, Animal; Electric Stimulation; Ele | 2002 |
Altered spatial distribution of PV-cortical cells and dysmorphic neurons in the somatosensory cortex of BCNU-treated rat model of cortical dysplasia.
Topics: Animals; Animals, Newborn; Antibodies; Calbindins; Carmustine; Classical Lissencephalies and Subcort | 2008 |